The World Health Organization took an important step in the fight against monkeypox with the announcement of the first vaccine against the disease. It was developed by Bavarian Nordic A/S, a biotechnology company located in Denmark.
WHO Director-General, Tedros Adhanom Ghebreyesusstressed the importance of the recent discovery: “This first prequalification of a monkeypox vaccine is an important step in our fight against the disease, both in the context of the current outbreaks in Africa and in the future“.
WHO approved the first vaccine against monkeypox
The new MVA-BN vaccine was included in the prequalification list. This approval is expected to significantly improve access to inoculation in regions with urgent outbreaksas is especially the case in Africa.
The injection is expected to contribute to current efforts to reduce transmission and control the spread of the disease across the planet. In addition, the WHO director general stressed the need to produce the vaccine on a large scale, in addition to improving distribution, to give a equitable access to those countries that are at greatest risk.
The vaccine itself is administered in two doses different that must be applied in a four-week range. In addition, its use is recommended in adults over 18 years of age.
According to the most recent studies, the vaccine is effective in a 76% after the first dose, a number that rises to 82% when applying the second of inoculation. Despite making the announcement, the world body emphasized the need to continue collecting data on the injection safety.
Monkeypox: the situation in Argentina
In Argentina, last Monday 7 new cases of this disease were confirmed – 5 of them within the City of Buenos Airesone in the Province and another in Córdoba – and in this way the registry of people in the country with this condition rose to 32In addition, the number of suspected infections reached 154.
Monkeypox.png
Through the Epidemiological BulletinThe Ministry of Health explained that, following the alert issued during Epidemiological Week 33, the sensitivity of the surveillance system increased due to the fact that 100 reports of suspected cases were received in the following two weeks.
The data showed that the populations most affected by this disease are men who have sexual practices with other men (65% of 20 cases that have data for the epidemiological variables). On this, the main risk factor It is the history of sexual relations with new, multiple and casual partners.
Of the 17 cases that have information regarding HIV status, 12 show co-infection with HIV. In it 100% of the cases that have Information on signs and symptoms The presence of rashes was detected in different locations of the body – genitals, perianal, hands, face and torso -, which are frequently followed by fever and myalgia.
Source: Ambito
